The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Succinate Dehydrogenase B Gene Mutations Predict Survival in Patients with Malignant Pheochromocytomas or Paragangliomas
Abstract
Context: Pheochromocytomas and paragangliomas may be malignant either at presentation or during recurrence, but the clinical course of malignant tumors is unpredictable. Objective: The objective was to analyze survival according to clinical characteristics at diagnosis of malignancy and the presence or absence of SDHB mutations. Design: This was a retrospective cohort study. Setting and Participants: A total of 54 patients with malignant tumors were included. Malignancy was scored according to the presence of metastases or histologically documented lymph node invasion. Main Outcome Measures: The main outcome was the specific survival after the diagnosis of the first metastasis. Results: Germline mutations were identified in SDHB (n = 23, including 21 patients with apparent sporadic tumors) and VHL (n = 1) genes, and two patients had neurofibromatosis 1. Patients were followed up from the diagnosis of primary tumor and from the diagnosis of the first metastasis to the present or to death with medians of 79 [interquartile range (IQR) 24; 190] and 39 [IQR 14; 94] months, respectively. The 5-yr probability of survival after the diagnosis of the first metastasis was 0.55 (95% confidence interval 0.39–0.69). Patients with SDHB mutations were younger, more frequently had extra-adrenal tumors, and had a shorter metanephrine excretion doubling time. The presence of SDHB mutations was significantly and independently associated with mortality (relative risk 2.7; 95% confidence interval 1.2, 6.4; P = 0.021). Conclusion: SDHB mutations, frequent in patients with malignant pheochromocytomas or paragangliomas, are associated with shorter survival. Therefore, SDHB genetic testing may be of prognostic value for such patients, even those with an apparent sporadic and/or benign presentation at diagnosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lenders, J. W., Eisenhofer, G., Mannelli, M., & Pacak, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,524
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Gutmann, D. H. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010065042 · Cited by 1,359
Rovelet-Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2006) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,249
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893
Genetic Testing in Pheochromocytoma or Functional Paraganglioma
Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1484 · Cited by 684
Self-citationMutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Gimenez‐Roqueplo, A., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Kien, P. K. V., Corvol, P. L., Plouin, P., & Jeunemaître, X. (2003) · PubMed · Cited by 609
Self-citationClinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes
Benn, D. E., Gimenez-Roqueplo, A.-P., Reilly, J. R., Bertherat, J., Burgess, J., Byth, K., Croxson, M., Dahia, P. L. M., Elston, M., Gimm, O., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1862 · Cited by 570
Self-citationClinical Experience Over 48 Years With Pheochromocytoma
Goldstein, R. E., O’Neill, J. A., Holcomb, G. W., Morgan, W. M., Neblett, W. W., Oates, J. A., Brown, N., Nadeau, J., Smith, B., Page, D. L., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00001 · Cited by 464
Amar, L., Servais, A., Gimenez-Roqueplo, A.-P., Zinzindohoue, F., Chatellier, G., & Plouin, P.-F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1398 · Cited by 390
Self-citationIlona Linnoila, R., Keiser, H. R., Steinberg, S. M., & Lack, E. E. (1990) · Human Pathology · doi:10.1016/0046-8177(90)90155-x · Cited by 374
Malignant pheochromocytoma: current status and initiatives for future progress
Eisenhofer, G., Bornstein, S. R., Brouwers, F. M., Cheung, N.-K. V., Dahia, P. L., de Krijger, R. R., Giordano, T. J., Greene, L. A., Goldstein, D. S., Lehnert, H., et al. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00829 · Cited by 338
Brouwers, F. M., Eisenhofer, G., Tao, J. J., Kant, J. A., Adams, K. T., Linehan, W. M., & Pacak, K. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0423 · Cited by 316
Timmers, H. J. L. M., Kozupa, A., Eisenhofer, G., Raygada, M., Adams, K. T., Solis, D., Lenders, J. W. M., & Pacak, K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2315 · Cited by 276
Pheochromocytomas: can malignant potential be predicted?
John, H., Ziegler, W. H., Hauri, D., & Jaeger, P. (1999) · Urology · doi:10.1016/s0090-4295(98)00612-8 · Cited by 251
Pheochromocytoma in Italy: a multicentric retrospective study
Mannelli, M., Ianni, L., Cilotti, A., & Conti, A. (1999) · European Journal of Endocrinology · doi:10.1530/eje.0.1410619 · Cited by 228
Functional Consequences of a SDHB Gene Mutation in an Apparently Sporadic Pheochromocytoma
Gimenez-Roqueplo, A.-P., Favier, J., Rustin, P., Rieubland, C., Kerlan, V., Plouin, P.-F., Rötig, A., & Jeunemaitre, X. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020525 · Cited by 209
Self-citationPhaeochromocytoma, new genes and screening strategies
Gimenez‐Roqueplo, A., Lehnert, H., Mannelli, M., Neumann, H., Opocher, G., Maher, E. R., Plouin, P., & on behalf of the European Network for the Study of Adrenal Tumours (ENS@T) Pheochromocytoma Working Group (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02714.x · Cited by 142
Self-citationMALIGNANT PHAEOCHROMOCYTOMA: CLINICAL, BIOCHEMICAL AND SCINTIGRAPHIC CHARACTERIZATION
Shapiro, B., Sisson, J. C., LLOYD, R., Nakajo, M., SATTERLEE, W. G., & Beierwaltes, W. H. (1984) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1984.tb00074.x · Cited by 131
Pheochromocytoma--continuing evolution of surgical therapy.
Orchard, T. J., Grant, C. S., van Heerden, J. A., & Weaver, A. L. (1993) · PubMed · Cited by 108
Douwes Dekker, P., Hogendoorn, P., Kuipers‐Dijkshoorn, N., Prins, F., van Duinen, S., Taschner, P., van der Mey, A., & Cornelisse, C. (2003) · The Journal of Pathology · doi:10.1002/path.1461 · Cited by 94
McWhinney, S. R., Pilarski, R. T., Forrester, S. R., Schneider, M. C., Sarquis, M. M., Dias, E. P., & Eng, C. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0769 · Cited by 89
The Urinary Metanephrine-to-Creatinine Ratio for the Diagnosis of Pheochromocytoma
Héron, E., Châtellier, G., Billaud, E., et al. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-4-199608150-00008 · Cited by 89
Long‐term Results in 64 Patients Operated Upon for Pheochromocytoma
Stenström, G., Ernest, I., & Tisell, L. (1988) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1988.tb15883.x · Cited by 54
Paraganglioma—All in the Family
Young, W. F., & Abboud, A. L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2758 · Cited by 50
Amar, L., Peyrard, S., Rossignol, P., Zinzindohoué, F., Gimenez‐Roqueplo, A., & Plouin, P. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.042 · Cited by 33
Self-citationThe genetic basis of pheochromocytoma: who to screen and how?
Plouin, P., & Gimenez‐Roqueplo, A. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0097 · Cited by 24
Self-citation
Cited by
Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline
Lenders, J. W. M., Duh, Q.-Y., Eisenhofer, G., Gimenez-Roqueplo, A.-P., Grebe, S. K. G., Murad, M. H., Naruse, M., Pacak, K., & Young, W. F. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1498 · Cited by 2,827
Self-citationSDH mutations establish a hypermethylator phenotype in paraganglioma
Letouzé, E., Martinelli, C., Loriot, C., Burnichon, N., Abermil, N., Ottolenghi, C., Janin, M., Menara, M., Nguyen, A. T., Benit, P., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.018 · Cited by 776
Self-citationPheochromocytoma and Paraganglioma
Neumann, H. P. H., Young, W. F., & Eng, C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806651 · Cited by 736
Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer
Wigerup, C., Påhlman, S., & Bexell, D. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.009 · Cited by 687
“Tumors with SDHB mutations seem to be more aggressive and metastatic (Amar et al., 2007; King et al., 2011), and although the molecular explanation for this phenomenon has not been fully established, a potential role for active HIF-2 signaling has been proposed (Guzy et al., 2008).”
BackgroundParaganglioma and phaeochromocytoma: from genetics to personalized medicine
Favier, J., Amar, L., & Gimenez-Roqueplo, A.-P. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.188 · Cited by 490
Self-citation
Metadata
- Authors
- Amar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., Jeunemaitre, X., Gimenez-Roqueplo, A.-P., & Plouin, P.-F.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2007-10-01
- Volume
- 92
- Issue
- 10
- Pages
- 3822-3828
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2032516847
- Cited by
- 450
- References
- 28
- FWCI
- 16.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.